乐鱼在线

Be the most trusted biotech company

2024-07-03

Henlius Forecasts Profit in 2023 H1: Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle
2024-06-28

Henlius Holds its 1st Overseas Scientific Advisory Board Meeting of 2023
2024-06-26

Henlius Immune Checkpoints Inhibitor Anti-CTLA-4 mAb Received IND Approval for the Treatment of HCC
2024-06-15

First Patient Dosed of Phase 2 Clinical Trial of Serplulimab in Combination with Innovative Anti-LAG-3 mAb for the Treatment of Metastatic Colorectal Cancer Patients
2024-06-12

Henlius Shines for Five Consecutive Years at BIO International Convention
2024-06-06

Results From the Phase 2 Clinical Trial of HLX07 for the Treatment of ESCC Released at 2023 ASCO
2024-06-06

Results From the Phase 2 Clinical Trial of Henlius BRAFV600E Inhibitor HLX208 for the Treatment of LCH and/or ECD Released at 2023 ASCO Annual Meeting
2024-05-26

2023 ASCO Annual Meeting Released Clinical Data of Two Henlius Trials
2024-05-26

Results from the Phase 3 Clinical Study of Novel Anti-PD-1 mAb Serplulimab for the First-line Treatment of ESCC Released at 2023 ASCO Annual Meeting

var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); 乐鱼在线官网-乐鱼在线 ufc下注官网_ufc竞猜平台【新版本下载】 ufc下注_ufc押注网站 ufc下注官网_ufc竞猜软件【注册登录】天博APP-天博APP下载-天博APP官方网站